StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) company profile

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$11.74−1.01 (-7.92%)

Close on Nov 17, 2026Market cap $79.70MP/E –Yield –

About Eloxx Pharmaceuticals

Biological Products, (No Diagnostic Substances), SIC 2836

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that engages in the research and development of pharmaceutical therapies. The company focuses primarily on developing its lead drug candidate, exaluren, which is undergoing clinical evaluation. Operating through a unified research and development segment, Eloxx enters into collaborative agreements, research arrangements, and licensing partnerships to progress its drug candidates. Because its programs remain in development stages, the company currently interacts with strategic collaborators, research foundations, and commercial licensing partners, such as Almirall and the Cystic Fibrosis Foundation, rather than selling finished products directly to commercial healthcare providers.

The company is headquartered in Arlington, Massachusetts. Its operations and clinical research activities extend internationally, with operational ties and regulatory exposure across the United States, Israel, and Australia. Physical scale includes leased office premises alongside specialized facilities equipped with laboratory apparatus, computer systems, and related research infrastructure to support its development activities.

Summary of the business section of Eloxx Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Eloxx Pharmaceuticals, Inc.
Headquarters
Arlington, MA
Address
P.O. Box 274 02476
Phone
(781) 577-5300
Employees
7, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, ewksbury, Massachusetts

Stock & identifiers

Ticker
ELOX
Former tickers
SVON until Mar 16, 2018; SNTI until Nov 14, 2014; SNT until Feb 14, 2013
Exchange
Nasdaq
IPO date
Jun 9, 2026
Shares outstanding
4M, Aug 7, 2026
Public float
$330.00K, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-40 reverse, Mar 31, 2023; 1-for-100 reverse, Nov 14, 2013
SEC CIK
1035354
CUSIP
29014R301
ISIN
US29014R3012
FIGI
BBG000BGGWS3
Share class FIGI
BBG001S799Q4
LEI
549300UB28QGWJMFFA11
EIN
84-1368850

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sumit AggarwalPresident and CEO, Director1,672,756
Geno J. GermanoDirector–
Nina S. KjellsonDirector–
Steven D. RubinDirector14,625
Stephen W. WebsterDirector–
Alan Edmund WaltsDirector15,567
Lindsay AndroskiDirector15,750

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 9, 2026
Offer price
$11.00
Securities offered
2,975,000
Gross proceeds
$32.73M
Exchange
Nasdaq
Lock-up ends (est.)
Dec 6, 2026

“(the “Company,” “Eloxx,” “we,” “our,” or “us”) is offering 2,975,000 shares of common stock, $0.01 par value per share, at the public offering price of $11.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had seven employees in the United States and three employees in Israel.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 9, 2026IPOInitial public offering priced (424B4 prospectus)
Jun 1, 2026ListingRegistration of securities on an exchange (Form 8-A)
Aug 14, 2025Late filingNotification of late filing
May 15, 2025Late filingNotification of late filing
Apr 1, 2025Late filingNotification of late filing
Nov 19, 2024Late filingNotification of late filing
Aug 14, 2024Late filingNotification of late filing
May 15, 2024Late filingNotification of late filing
Apr 1, 2024Late filingNotification of late filing
Mar 21, 2024DelistingNotice of delisting from exchange (Form 25)
Oct 16, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 14, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 14, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 14, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 15, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 5, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 5, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 1, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 21, 2018Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 24, 2018ListingRegistration of securities on an exchange (Form 8-A)
Dec 22, 2017Name changeName changed from Sevion Therapeutics, Inc. to Eloxx Pharmaceuticals, Inc.
Dec 22, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 22, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 28, 2017Late filingNotification of late filing
May 15, 2017Late filingNotification of late filing
Sep 28, 2016Late filingNotification of late filing
Sep 28, 2015Late filingNotification of late filing
Sep 29, 2014Name changeName changed from SENESCO TECHNOLOGIES INC to Sevion Therapeutics, Inc.
May 19, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 23, 2012DelistingNotice of delisting from exchange (Form 25)

See a number that looks wrong?